Entity Details

Primary name ANT3_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionP01008
EntryNameANT3_HUMAN
FullNameAntithrombin-III
TaxID9606
Evidenceevidence at protein level
Length464
SequenceStatuscomplete
DateCreated1986-07-21
DateModified2021-06-02

Ontological Relatives

GenesSERPINC1

GO terms

Show/Hide Table
GOName
GO:0002020 protease binding
GO:0002438 acute inflammatory response to antigenic stimulus
GO:0004867 serine-type endopeptidase inhibitor activity
GO:0005576 extracellular region
GO:0005615 extracellular space
GO:0005788 endoplasmic reticulum lumen
GO:0005886 plasma membrane
GO:0007584 response to nutrient
GO:0007595 lactation
GO:0007596 blood coagulation
GO:0008201 heparin binding
GO:0010951 negative regulation of endopeptidase activity
GO:0042802 identical protein binding
GO:0043687 post-translational protein modification
GO:0044267 cellular protein metabolic process
GO:0062023 collagen-containing extracellular matrix
GO:0070062 extracellular exosome
GO:0072562 blood microparticle
GO:2000266 regulation of blood coagulation, intrinsic pathway

Subcellular Location

Show/Hide Table
Subcellular Location
Secreted

Domains

Show/Hide Table
DomainNameCategoryType
IPR000215 Serpin familyFamilyFamily
IPR015555 Antithrombin-IIIFamilyFamily
IPR023795 Serpin, conserved siteSiteConserved site
IPR023796 Serpin domainDomainDomain
IPR033829 Antithrombin-III, serpin domainDomainDomain
IPR036186 Serpin superfamilyFamilyHomologous superfamily
IPR042178 Serpin superfamily, domain 1FamilyHomologous superfamily
IPR042185 Serpin superfamily, domain 2FamilyHomologous superfamily

Diseases

Show/Hide Table
Disease IDSourceNameDescription
613118 OMIMAntithrombin III deficiency (AT3D)An important risk factor for hereditary thrombophilia, a hemostatic disorder characterized by a tendency to recurrent thrombosis. Antithrombin-III deficiency is classified into 4 types. Type I: characterized by a 50% decrease in antigenic and functional levels. Type II: has defects affecting the thrombin-binding domain. Type III: alteration of the heparin-binding domain. Plasma AT-III antigen levels are normal in type II and III. Type IV: consists of miscellaneous group of unclassifiable mutations. The disease is caused by variants affecting the gene represented in this entry.

Drugs

Show/Hide Table
DrugNameSourceType
DB00407 ArdeparinDrugbanksmall molecule
DB00569 FondaparinuxDrugbanksmall molecule
DB01109 HeparinDrugbanksmall molecule
DB01225 EnoxaparinDrugbanksmall molecule
DB04464 N-FormylmethionineDrugbanksmall molecule
DB05361 SR-123781ADrugbanksmall molecule
DB06271 SulodexideDrugbankbiotech
DB06754 DanaparoidDrugbanksmall molecule
DB06779 DalteparinDrugbanksmall molecule
DB06822 TinzaparinDrugbanksmall molecule
DB08813 NadroparinDrugbanksmall molecule
DB09130 CopperDrugbanksmall molecule
DB09141 Protamine sulfateDrugbankbiotech
DB09258 BemiparinDrugbanksmall molecule
DB11598 Antithrombin III humanDrugbankbiotech